BioTherapeutics is committed to developing therapies with the aim of saving and sustaining lives. Our aim is to provide the highest quality products and programs that advance patient care globally and enable the achievement of outcomes through innovation, science, and technology.
The BioTherapeutics' team specializes in three key therapeutic areas: immunoglobulins, pulmonology, and critical care therapies. BioTherapeutics' immunoglobulin therapies treat primary immunodeficiencies associated with defects in humoral immunity or a lack of antibody production. BioTherapeutics also produces antibody-replacement therapies to bolster the immune system of people with secondary immunodeficiencies and recurrent infections. Immunoglobulin therapies also include treatments for ITP in patients with low platelet counts.
Read More [+]
ISTANBUL, October 6, 2010 - Data from interim analyses of a Phase III clinical study in patients with primary immune deficiency (PID) who received Baxter's HyQ were presented at the 26th meeting of the European Society for Immunodeficiencies (ESID) in Istanbul, Turkey. HyQ is an immune globulin (IG) therapy facilitated subcutaneously by recombinant human hyaluronidase, a dispersion and permeation enhancer.
Read More [+]
Deerfield, IL, April 29, 2010 - Today, Baxter International, Inc. and the Jeffrey Modell Foundation (JMF) are supporting expanded global activities in conjunction with the 6th annual World Day of Immunology.
Read More [+]
A sterile, nonpyrogenic preparation of albumin in a single-dosage
Sterile, stable, lyophilized preparation of purified alpha 1-proteinase inhibitor
